Evelo Biosciences to Present at Jefferies Virtual Healthcare Conference
Evelo Biosciences, a clinical stage biotechnology company, has announced its participation in a fireside chat at the Jefferies Virtual Healthcare Conference on June 4th at 4:30 p.m. ET. Investors can access the live audio webcast via the company's website, with a replay available for 30 days afterward. Evelo develops orally delivered biologics targeting the small intestinal axis, aiming to treat inflammatory diseases and cancer. Their product pipeline includes candidates EDP1815, EDP1867, EDP2939 for inflammation, and EDP1503 for cancer. Visit their website for more information.
- None.
- None.
CAMBRIDGE, Mass., May 28, 2020 (GLOBE NEWSWIRE) -- Evelo Biosciences, Inc. (Nasdaq:EVLO), a clinical stage biotechnology company developing a new modality of orally delivered, systemically acting biologics, today announced that management will participate in a fireside chat at the Jefferies Virtual Healthcare Conference on Thursday, June 4th at 4:30 p.m. ET.
A live audio webcast of the presentation will be available on the Investors section of the Evelo website at http://ir.evelobio.com/news-events. A replay of the webcast will be available for approximately 30 days following the presentation.
About Evelo Biosciences
Evelo Biosciences is a clinical stage biotechnology company developing oral biologics that act on SINTAX™, the small intestinal axis, with systemic therapeutic effects. SINTAX plays a central role in governing the immune, metabolic, and neurological systems. The company’s first product candidates are monoclonal microbials, single strains of microbes selected for defined pharmacological properties. Evelo’s therapies have the potential to be effective, safe, and affordable medicines to improve the lives of people with inflammatory diseases and cancer.
Evelo currently has four product candidates: EDP1815, EDP1867, and EDP2939 for the treatment of inflammatory diseases, and EDP1503 for the treatment of cancer. Evelo is also advancing additional oral biologics through preclinical development in other disease areas.
For more information, please visit www.evelobio.com and engage with Evelo on LinkedIn.
Contact
Evelo Biosciences
Jessica Cotrone, 978-760-5622
jcotrone@evelobio.com
FAQ
What is Evelo Biosciences' participation in the Jefferies Virtual Healthcare Conference?
How can I listen to the Evelo Biosciences presentation at the conference?
What are the product candidates of Evelo Biosciences?
What is the focus of Evelo Biosciences' research?
Where can I find more information about Evelo Biosciences?
